Home>Topics>Stocks>Roche Holding AG ADR

Roche Holding AG ADR RHHBY

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
    1. FDA approves Zydelig for three types of blood cancers

      Headlines

      Wed, 23 Jul 2014

      treatment for chronic lymphocytic leukemia (CLL) that has relapsed. Zydelig is to used with Rituxan ( rituximab ) ( OTCQX: RHHBY +0.3% ) ( BIIB +11.6% ) in cases where Rituxan alone is appropriate therapy. In a Phase 3 clinical trial, patients

    2. Puma explodes AH

      Headlines

      Tue, 22 Jul 2014

      enrolled 2,821 patients in 41 countries who had undergone surgery and adjuvant treatment with Herceptin ( trastuzumab ) ( OTCQX: RHHBY ). After treatment with trastuzumab, patients were randomized to receive adjuvant treatment with neratinib or placebo for

    3. Priority review for Avastin

      Headlines

      Tue, 22 Jul 2014

      The FDA accepts Genentech's ( OTCQX: RHHBY ) sBLA for Avastin ( bevacizumab ) plus chemotherapy for the treatment of women with recurrent platinum-resistant ovarian cancer

    4. Pfenex debuts tomorrow

      Headlines

      Mon, 21 Jul 2014

      high value proteins focused on biosimilars. Its lead product candidate is PF582, a biosimilar version of Roche's ( OTCQX: RHHBY -0.1% ) Lucentis (ranibizumab). It is currently being evaluated in a Phase 1b/2a clinical trial. Top-line data from

    5. Roche to continue focusing on small-scale acquisitions

      Headlines

      Sun, 20 Jul 2014

      Roche ( OTCQX: RHHBY ) plans to continue its strategy of focusing on smaller acquisitions and partnerships rather than the big M&A deals that have

    6. Crenezumab benefits in Alzheimer's uncertain

      Headlines

      Wed, 16 Jul 2014

      In two Phase 2 clinical trials evaluating the safety and efficacy of Roche's ( OTCQX: RHHBY -1.1% ) crenezumab as a treatment to delay cognitive and functional decline in patients with mild-to-moderate Alzheimer's

    7. Avastin + chemo gets priority review for cervical cancer

      Headlines

      Tue, 15 Jul 2014

      The FDA designates Genentech's ( OTCQX: RHHBY +1.1% ) sBLA for Avastin (bevacizumab) plus chemotherapy as a treatment for persistent, recurrent or metastatic cervical

    8. Traders pile into Exelixis

      Headlines

      Mon, 14 Jul 2014

      Zelboraf in BRAF-mutated melanoma. Rumors are building that the company is an attractive takeout candidate for Roche ( OTCQX: RHHBY +1.1% ) in light of Genentech's close relationship with the firm and the $1B potential sales of the combo therapy. Post

    9. Healthcare player Miller believes Roche will gobble up Exelixis

      Headlines

      Mon, 14 Jul 2014

      In an interview with TheStreet's Adam Feuerstein, David Miller elaborates on his view that Roche ( OTCQX: RHHBY +1.3% ) has a strong incentive to acquire Exelixis ( EXEL +10.7% ) in order to capture the full margin of the combination

    10. MannKind: Are These Top Big Pharma Companies Potential Partners?

      Headlines

      Mon, 14 Jul 2014

      By Psycho Analyst : Now that the FDA has approved MannKind's (NASDAQ: MNKD ) inhaled insulin, Afrezza, investors are anxiously awaiting news as to what company, if any, will partner with MNKD to market and distribute this new, potentially blockbusting drug. Though there has been no shortage of ...

    « Prev12345Next »
    Content Partners